beta
Text
1. The plaintiff's claim is dismissed.
2. The costs of lawsuit shall be borne by the Plaintiff.
Reasons
1. Basic facts
A. The Plaintiff concluding an insurance contract is a company running non-life insurance business.
On September 18, 2012, the Plaintiff entered into each insurance contract (hereinafter “each insurance contract of this case”) with respect to the "Undividend-based comprehensive insurance contract (hereinafter “instant insurance contract”) with the content that the insured and the beneficiary (the beneficiary at the time of death) shall pay KRW 20 million insurance money at the time the diagnosis becomes final and conclusive, and KRW 20 million insurance money at the time of cancer operation,” with the Defendant, “Aam on October 19, 2012,” respectively, to pay KRW 1 million insurance money at the time the diagnosis becomes final and conclusive, and KRW 50 million at the time of the second cancer diagnosis (the beneficiary at the time of death).
B. The contents of the insurance contract of this case are as follows: 1. The terms and conditions of the insurance contract of this case concerning cancer diagnosis expenses included in each insurance contract of this case are as follows: 45. [The definitions and diagnosis confirmation of Article 2(Aam, 'other skin cancer', and 'Aamam') of the terms and conditions of the cancer diagnosis expenses, 45. 1. The term 'am' in this contract refers to diseases (attached Table 2) classified as malicious organisms in the Korean Standard Disease Classification, 6. (See Table 2). However, the classification code 344 (Other Aamsive Organisms.)", the classification code C73 (Aams. Mas. Mas. Mas. Mas. Mas. Mas. Mas. Mas. Mas. Mas. Mas. Mas. Mas. Mas. Mas. Mas. Mas. Mas. Mas. Mas.
(2) In this Agreement, the term "other skin cancer" means a disease falling under the classification number C44 (other malicious life of the skin) of attached Table 2 (C44 (Cr.m.) from among the terms in paragraph (1).
(3) In this contract, the term "Ampiram" means the "Ampiram" as provided in paragraph (1) of this Article.